Brandes Investment Partners LP Has $33.76 Million Stock Holdings in Sanofi (NASDAQ:SNY)

Brandes Investment Partners LP lessened its stake in Sanofi (NASDAQ:SNYGet Rating) by 5.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 657,487 shares of the company’s stock after selling 40,601 shares during the quarter. Brandes Investment Partners LP’s holdings in Sanofi were worth $33,755,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Boston Partners increased its stake in shares of Sanofi by 62.3% during the 1st quarter. Boston Partners now owns 11,272,368 shares of the company’s stock worth $580,302,000 after purchasing an additional 4,328,799 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Sanofi by 3.0% during the 4th quarter. Bank of America Corp DE now owns 10,539,487 shares of the company’s stock worth $528,028,000 after purchasing an additional 305,627 shares during the last quarter. Lazard Asset Management LLC increased its stake in shares of Sanofi by 2.8% during the 4th quarter. Lazard Asset Management LLC now owns 3,296,264 shares of the company’s stock worth $165,142,000 after purchasing an additional 90,994 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Sanofi by 29.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,227,680 shares of the company’s stock worth $111,607,000 after buying an additional 506,752 shares during the period. Finally, Hamlin Capital Management LLC boosted its holdings in shares of Sanofi by 2.0% during the 1st quarter. Hamlin Capital Management LLC now owns 1,888,304 shares of the company’s stock worth $96,946,000 after buying an additional 37,622 shares during the period. Institutional investors and hedge funds own 12.82% of the company’s stock.

Wall Street Analyst Weigh In

SNY has been the subject of several recent analyst reports. UBS Group downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday, August 9th. StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a report on Sunday. Guggenheim upped their price objective on shares of Sanofi from €121.00 ($123.47) to €127.00 ($129.59) in a report on Monday, May 2nd. Morgan Stanley upped their price objective on shares of Sanofi from €110.00 ($112.24) to €112.00 ($114.29) in a report on Friday, April 22nd. Finally, SVB Leerink initiated coverage on shares of Sanofi in a report on Monday, May 23rd. They issued an “outperform” rating for the company. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi currently has a consensus rating of “Moderate Buy” and a consensus price target of $111.14.

Sanofi Price Performance

Shares of NASDAQ:SNY traded down $3.15 during midday trading on Wednesday, reaching $41.66. 228,571 shares of the company’s stock were exchanged, compared to its average volume of 3,358,294. The company’s 50 day simple moving average is $49.08 and its two-hundred day simple moving average is $50.97. The firm has a market capitalization of $105.44 billion, a PE ratio of 13.86, a price-to-earnings-growth ratio of 1.05 and a beta of 0.48. Sanofi has a 12 month low of $41.91 and a 12 month high of $58.10. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.34 and a current ratio of 1.29.

Sanofi (NASDAQ:SNYGet Rating) last released its quarterly earnings data on Thursday, July 28th. The company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.07. The company had revenue of $10.78 billion during the quarter, compared to the consensus estimate of $10.32 billion. Sanofi had a net margin of 16.60% and a return on equity of 25.99%. Equities research analysts expect that Sanofi will post 4.12 earnings per share for the current fiscal year.

Sanofi Profile

(Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

See Also

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.